The AutoSTEA device, developed by MetroHealth Medical Center, aims to address functional dyspepsia, a condition affecting a significant portion of the adult population. The feasibility trial will assess both the efficacy and safety of the device, which could position it as a novel non-pharmacological treatment option in a market currently dominated by pharmacotherapy. Given the increasing prevalence of functional gastrointestinal disorders and the growing demand for at-home treatment solutions, successful outcomes could lead to a competitive advantage in the gastrointestinal device market. However, the trial's limited enrollment of 20 participants may pose challenges in establishing robust market claims. The focus on usability and safety is critical for patient acceptance and adherence, which are essential for commercial success.